Trials / Completed
CompletedNCT04466215
Medication Development for Protracted Abstinence in Alcoholism: CORT118335 Versus Placebo
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- The Scripps Research Institute · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The hypotheses under test are that subjects with alcohol use disorder (AUD) of moderate or greater severity treated with CORT118335 will report decreased craving for alcohol following alcohol exposure in the laboratory and report significantly less drinking under naturalistic conditions, than those treated with placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Miricorilant | 900 mg (6 x 150 mg) tablets taken orally once daily for two weeks |
| DRUG | Placebo oral tablet | Six placebo tablets taken orally once daily for two weeks |
Timeline
- Start date
- 2021-04-15
- Primary completion
- 2022-04-15
- Completion
- 2022-06-07
- First posted
- 2020-07-10
- Last updated
- 2023-02-03
- Results posted
- 2023-02-03
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04466215. Inclusion in this directory is not an endorsement.